Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [4150]

Aspirin in stage III colorectal cancer shows no significant DFS benefit but...

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

Amivantamab in HPV-unrelated mHNSCC gives high response rates after...

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness - Yale Cancer Center, New Haven, USA )

GLP-1 therapy associated with reduced breast cancer risk

Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA

GLP-1 therapy associated with reduced breast cancer risk ( Dr Elizabeth McDonald - University of Pennsylvania, Philadelphia, USA )

Gene expression test guided therapy in ER+/HER2- early breast cancer allows...

Dr Robert Stein - University College London, London, UK

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

MCED blood test trial fails primary end point, but screening cut number of...

Dr Peter Sasieni - Queen Mary University of London, London, UK

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV ( Dr Peter Sasieni - Queen Mary University of London, London, UK )

Fedratinib improves spleen and symptom responses with promising survival...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

GLP-1 use linked to improved survival in patients with cancer

Dr Jessica Paulus - Ontada, Boston, USA

GLP-1 use linked to improved survival in patients with cancer ( Dr Jessica Paulus - Ontada, Boston, USA )

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic...

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )

Early-onset gastrointestinal cancers show more advanced disease and wider...

Dr Jessica Paulus - Ontada, Boston, USA

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )

More from ecancer